Sfoglia per Autore
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Barletta, M. T.; Bocci, Guido; Allegrini, G.; Masi, G.; Giuntini, N.; Coltelli, L.; Bona, E.; Loupakis, F.; DI LEO, A.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; Falcone, Alfredo
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer
2008-01-01 DI PAOLO, Antonello; Lencioni, M; Amatori, F; DI DONATO, S; Bocci, Guido; Orlandini, C; Lastella, M; Federici, F; Iannopollo, M; Falcone, Alfredo; Ricci, S; DEL TACCA, M; Danesi, Romano
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
2008-01-01 Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
2008-01-01 A., Fontana; Bocci, Guido; M., Darcangelo; L., Galli; C., Galli; S., Bursi; L., Landi; A., Antonuzzo; M., DEL TACCA; Falcone, Alfredo
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; DI LEO, A.; Falcone, Alfredo
Pharmacogenetics of Antiangiogenic Therapy
2008-01-01 Bocci, Guido; Pasqualetti, Giuseppe; DI PAOLO, Antonello; Del Tacca, M.; Danesi, Romano
Pharmacogenetics in oncology
2008-01-01 Danesi, Romano; DI PAOLO, Antonello; Bocci, Guido; Crea, F; DEL TACCA, M.
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
2008-01-01 Bocci, Guido; Falcone, Alfredo; Fioravanti, A; Orlandi, P; DI PAOLO, Antonello; Fanelli, G; Viacava, P; Naccarato, ANTONIO GIUSEPPE; Kerbel, Rs; Danesi, Romano; DEL TACCA, M; Allegrini, G.
Docetaxel (D) Plus Prednisone (P) in Combination with Metronomic Cyclophosphamide (CTX) and Celecoxib (C) as First Line Treatment in Metastatic Hormone Refractory Prostate Cancer (MHRPC): a Phase II Clinical Trial with Pharmacodynamic Evaluation
2008-01-01 A., Fontana; Bocci, Guido; M., Darcangelo; L., Galli; S., Bursi; L., Landi; P., Battaglini; S., Caponi; M., DEL TACCA; Falcone, Alfredo
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
2008-01-01 Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX), and celecoxib in pretreated patients with advanced gastrointestinal cancers: A pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2009-01-01 Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fontana, A.; DI LEO, A.; Bardi, G.; Kerbel, R.; DEL TACCA, M.; Falcone, Alfredo
Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)
2009-01-01 A., Fontana; L., Galli; L., Derosa; G., Minuti; M., Darcangelo; S., Bursi; L., Landi; Bocci, Guido; D., Santini; Falcone, Alfredo
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)
2009-01-01 A., Fontana; Bocci, Guido; L., Galli; L., Derosa; G., Minuti; M., Darcangelo; D., Santini; L., Landi; S., Bursi; Falcone, Alfredo
Metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2009-01-01 L., Galli; A., Fontana; L., Derosa; G., Minuti; M., Darcangelo; E., Fontana; V., Safina; L., Landi; S., Bursi; C., Galli; E., Bona; Bocci, Guido; A., Antonuzzo; Falcone, Alfredo
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer
2009-01-01 Fioravanti, A; Canu, B; Alì, G; Orlandi, P; Allegrini, G; DI DESIDERO, T; Emmenegger, U; Fontanini, Gabriella; Danesi, Romano; DEL TACCA, Mario; Falcone, Alfredo; Bocci, Guido
Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue
2009-01-01 Bocci, Guido; Fasciani, A; Orlandi, P; DI PAOLO, Antonello; DEL TACCA, M; Danesi, Romano
Tossicologia dei farmaci biotecnologici
2009-01-01 DI PAOLO, Antonello; Bocci, Guido; Danesi, Romano; DEL TACCA, M.
Docetaxel-prednisone (DP) plus metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC): phase II trial with pharmacodynamic evaluation
2009-01-01 A., Fontana; L., Galli; L., Derosa; G., Minuti; M., Darcangelo; E., Fontana; R., DI MARSICO; O., Venditti; S., Galluzzo; L., Landi; S., Bursi; C., Galli; E., Bona; Bocci, Guido; A., Antonuzzo; Falcone, Alfredo
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis
2009-01-01 Coltelli, L; Allegrini, G; Orlandi, P; Giuntini, N; Alì, G; Fioravanti, A; Bona, E; Barletta, Mt; Fontanini, Gabriella; DEL TACCA, Mario; Danesi, Romano; Falcone, Alfredo; Bocci, Guido
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
2009-01-01 L., Coltelli; G., Allegrini; Orlandi, Paola; N., Giuntini; G., Alì; Fioravanti, Anna; E., Bona; M. T., Barletta; Fontanini, Gabriella; M., Del Tacca; Danesi, Romano; Falcone, Alfredo; Bocci, Guido
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Barletta, M. T.; Bocci, Guido; Allegrini, G.; Masi, G.; Giuntini, N.; Coltelli, L.; Bona, E.; Loupakis, F.; DI LEO, A.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; Falcone, Alfredo | |
| 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer | 1-gen-2008 | DI PAOLO, Antonello; Lencioni, M; Amatori, F; DI DONATO, S; Bocci, Guido; Orlandini, C; Lastella, M; Federici, F; Iannopollo, M; Falcone, Alfredo; Ricci, S; DEL TACCA, M; Danesi, Romano | |
| Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction | 1-gen-2008 | Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano | |
| Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation | 1-gen-2008 | A., Fontana; Bocci, Guido; M., Darcangelo; L., Galli; C., Galli; S., Bursi; L., Landi; A., Antonuzzo; M., DEL TACCA; Falcone, Alfredo | |
| Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; DI LEO, A.; Falcone, Alfredo | |
| Pharmacogenetics of Antiangiogenic Therapy | 1-gen-2008 | Bocci, Guido; Pasqualetti, Giuseppe; DI PAOLO, Antonello; Del Tacca, M.; Danesi, Romano | |
| Pharmacogenetics in oncology | 1-gen-2008 | Danesi, Romano; DI PAOLO, Antonello; Bocci, Guido; Crea, F; DEL TACCA, M. | |
| Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib | 1-gen-2008 | Bocci, Guido; Falcone, Alfredo; Fioravanti, A; Orlandi, P; DI PAOLO, Antonello; Fanelli, G; Viacava, P; Naccarato, ANTONIO GIUSEPPE; Kerbel, Rs; Danesi, Romano; DEL TACCA, M; Allegrini, G. | |
| Docetaxel (D) Plus Prednisone (P) in Combination with Metronomic Cyclophosphamide (CTX) and Celecoxib (C) as First Line Treatment in Metastatic Hormone Refractory Prostate Cancer (MHRPC): a Phase II Clinical Trial with Pharmacodynamic Evaluation | 1-gen-2008 | A., Fontana; Bocci, Guido; M., Darcangelo; L., Galli; S., Bursi; L., Landi; P., Battaglini; S., Caponi; M., DEL TACCA; Falcone, Alfredo | |
| A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. | 1-gen-2008 | Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido | |
| Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX), and celecoxib in pretreated patients with advanced gastrointestinal cancers: A pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2009 | Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fontana, A.; DI LEO, A.; Bardi, G.; Kerbel, R.; DEL TACCA, M.; Falcone, Alfredo | |
| Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC) | 1-gen-2009 | A., Fontana; L., Galli; L., Derosa; G., Minuti; M., Darcangelo; S., Bursi; L., Landi; Bocci, Guido; D., Santini; Falcone, Alfredo | |
| Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts) | 1-gen-2009 | A., Fontana; Bocci, Guido; L., Galli; L., Derosa; G., Minuti; M., Darcangelo; D., Santini; L., Landi; S., Bursi; Falcone, Alfredo | |
| Metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2009 | L., Galli; A., Fontana; L., Derosa; G., Minuti; M., Darcangelo; E., Fontana; V., Safina; L., Landi; S., Bursi; C., Galli; E., Bona; Bocci, Guido; A., Antonuzzo; Falcone, Alfredo | |
| Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer | 1-gen-2009 | Fioravanti, A; Canu, B; Alì, G; Orlandi, P; Allegrini, G; DI DESIDERO, T; Emmenegger, U; Fontanini, Gabriella; Danesi, Romano; DEL TACCA, Mario; Falcone, Alfredo; Bocci, Guido | |
| Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue | 1-gen-2009 | Bocci, Guido; Fasciani, A; Orlandi, P; DI PAOLO, Antonello; DEL TACCA, M; Danesi, Romano | |
| Tossicologia dei farmaci biotecnologici | 1-gen-2009 | DI PAOLO, Antonello; Bocci, Guido; Danesi, Romano; DEL TACCA, M. | |
| Docetaxel-prednisone (DP) plus metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC): phase II trial with pharmacodynamic evaluation | 1-gen-2009 | A., Fontana; L., Galli; L., Derosa; G., Minuti; M., Darcangelo; E., Fontana; R., DI MARSICO; O., Venditti; S., Galluzzo; L., Landi; S., Bursi; C., Galli; E., Bona; Bocci, Guido; A., Antonuzzo; Falcone, Alfredo | |
| Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis | 1-gen-2009 | Coltelli, L; Allegrini, G; Orlandi, P; Giuntini, N; Alì, G; Fioravanti, A; Bona, E; Barletta, Mt; Fontanini, Gabriella; DEL TACCA, Mario; Danesi, Romano; Falcone, Alfredo; Bocci, Guido | |
| Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. | 1-gen-2009 | L., Coltelli; G., Allegrini; Orlandi, Paola; N., Giuntini; G., Alì; Fioravanti, Anna; E., Bona; M. T., Barletta; Fontanini, Gabriella; M., Del Tacca; Danesi, Romano; Falcone, Alfredo; Bocci, Guido |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile